Back to Search
Start Over
Comparison of Plasma and Intrapulmonary Concentrations of Nafithromycin (WCK 4873) in Healthy Adult Subjects
- Source :
- Antimicrobial Agents and Chemotherapy. 61
- Publication Year :
- 2017
- Publisher :
- American Society for Microbiology, 2017.
-
Abstract
- The nafithromycin concentrations in the plasma, epithelial lining fluid (ELF), and alveolar macrophages (AM) of 37 healthy adult subjects were measured following repeated dosing of oral nafithromycin at 800 mg once daily for 3 days. The values of noncompartmental pharmacokinetic (PK) parameters were determined from serial plasma samples collected over a 24-h interval following the first and third oral doses. Each subject underwent one standardized bronchoscopy with bronchoalveolar lavage (BAL) at 3, 6, 9, 12, 24, or 48 h after the third dose of nafithromycin. The mean ± standard deviation values of the plasma PK parameters after the first and third doses included maximum plasma concentrations ( C max ) of 1.02 ± 0.31 μg/ml and 1.39 ± 0.36 μg/ml, respectively; times to C max of 3.97 ± 1.30 h and 3.69 ± 1.28 h, respectively; clearances of 67.3 ± 21.3 liters/h and 52.4 ± 18.5 liters/h, respectively, and elimination half-lives of 7.7 ± 1.1 h and 9.1 ± 1.7 h, respectively. The values of the area under the plasma concentration-time curve (AUC) from time zero to 24 h postdosing (AUC 0–24 ) for nafithromycin based on the mean or median total plasma concentrations at BAL fluid sampling times were 16.2 μg · h/ml. For ELF, the respective AUC 0–24 values based on the mean and median concentrations were 224.1 and 176.3 μg · h/ml, whereas for AM, the respective AUC 0–24 values were 8,538 and 5,894 μg · h/ml. Penetration ratios based on ELF and total plasma AUC 0–24 values based on the mean and median concentrations were 13.8 and 10.9, respectively, whereas the ratios of the AM to total plasma concentrations based on the mean and median concentrations were 527 and 364, respectively. The sustained ELF and AM concentrations for 48 h after the third dose suggest that nafithromycin has the potential to be a useful agent for the treatment of lower respiratory tract infections. (This study has been registered at ClinicalTrials.gov under registration no. NCT02453529.)
- Subjects :
- Adult
Male
0301 basic medicine
Ketolides
Staphylococcus aureus
030106 microbiology
Cmax
Repeated dosing
Bronchoalveolar Lavage
030226 pharmacology & pharmacy
Legionella pneumophila
Lactones
Young Adult
03 medical and health sciences
0302 clinical medicine
Animal science
Pharmacokinetics
Bronchoscopy
Macrophages, Alveolar
Pneumonia, Bacterial
Humans
Pharmacology (medical)
Pharmacology
Time zero
Total plasma
Plasma samples
Chemistry
Epithelial lining fluid
PK Parameters
Chlamydophila pneumoniae
Middle Aged
Haemophilus influenzae
Healthy Volunteers
Anti-Bacterial Agents
Mycoplasma pneumoniae
Pulmonary Alveoli
Streptococcus pneumoniae
Infectious Diseases
Female
Bronchoalveolar Lavage Fluid
Moraxella catarrhalis
Subjects
Details
- ISSN :
- 10986596 and 00664804
- Volume :
- 61
- Database :
- OpenAIRE
- Journal :
- Antimicrobial Agents and Chemotherapy
- Accession number :
- edsair.doi.dedup.....d599715e3e06baf4d326b2d136956fd0
- Full Text :
- https://doi.org/10.1128/aac.01096-17